BioNTech's Richardson on Drug Pipeline

from Vanguards of Health Care by Bloomberg Intelligence · host Bloomberg

BioNTech has a broad and diversified cancer drug pipeline extending well beyond mRNA based approaches. Sam Fazeli, Senior Health Care Analyst, speaks to Ryan Richardson, Chief Strategy Officer, who explains the company’s approach to drug development, hopes for drug launches and what sets it apart from rivals.See omnystudio.com/listener for privacy information.

Episode metadata supplied by the publisher feed · Published Oct 3, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

BioNTech's Richardson on Drug Pipeline

0:00 37:50

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Vanguards of Health Care by Bloomberg Intelligence?

This episode is 37 minutes long.

When was this Vanguards of Health Care by Bloomberg Intelligence episode published?

This episode was published on October 3, 2024.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Vanguards of Health Care by Bloomberg Intelligence episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!